RxDoctor Payments Data

Olivia Desena

Nurse Practitioner · Biddeford, MENPI 1972141034

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,051 of the $1,181 with a category attached, or 88.9%. It is spread thinly across 9 manufacturers, the largest accounting for just 21.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $482, 4.0 times the $121 reported in 2022. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,181in general payments, 2019–2025

Across 11 payments — averaging $107.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$250
  • Pfizer$203
  • Teleflex LLC$126
  • E.r. Squibb & Sons, L.L.C.$121
  • Seagen Inc.$117
  • Adaptive Biotechnologies Corporation$116
  • plus $248 from 3 others

What the payments were for

  • Food & beverage$1,05189%
  • Education$13111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,181 in reported general payments places this provider in the 95th percentile of 740 nurse practitioner providers in Maine.

See all nurse practitioner providers in Maine

Medicare billing

Part B allowed, 2024
$28,375
Medicare patients
88
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban22$17,246
Tranexamic Acid12$1,769
Acyclovir96$1,677
Hydroxyurea41$812
Dexamethasone33$562
Omeprazole27$425
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim38$379
Gabapentin16$356
Oxycodone Hcl22$198
Ondansetron Hcl11$191
Prochlorperazine Maleate13$142
Prednisone17$142
Allopurinol17$55
Fluoxetine Hcl11$30
Lorazepam13$11

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$17,24622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 740 nurse practitioner providers in Maine.

Other nurse practitioner in Biddeford

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →